Interview with the CEO: Nuvectra Corporation (NASDAQ:NVTR)

Healthcare >> CEO Interviews >> July 29, 2016

Scott Drees is Chief Executive Officer of Nuvectra Corporation. Prior to joining Nuvectra as CEO, Mr. Drees was a founding partner of Algostim LLC and Pelvistim LLC, and served as a full-time consultant to QiG Group LLC, a wholly owned subsidiary of Greatbatch, Inc. — now Integer Holdings — since 2009. From January 2008 to July 2015, Mr. Drees also served as the President and CEO of Neuromodulation Ventures, LLC, a private company focused on incubating new neurostimulation companies. Mr. Drees has 35 years of experience in the medical device industry and has spent his last 20 years focused on neuromodulation markets and therapies. He has served in executive positions from 1996 to 2006, as founding Division President and later Executive VP, Worldwide Sales & Marketing at Advanced Neuromodulation Systems, Inc., or ANSI, a company acquired by St. Jude Medical, Inc., in 2005. Between 1981 and 1996, Mr. Drees held a variety of positions at St. Jude Medical, Boston Scientific, and Johnson and Johnson’s Codman Division. Mr. Drees currently serves as a director of Neuros Medical, Inc., a privately held neurostimulation company and was a founding member of the National Pain Foundation. He earned his B.S. degree from St. Joseph’s University, Philadelphia. Profile

TWST: Could you tell our readers what Nuvectra is and why you call yourselves a new kind of medical device company?

Mr. Drees: Nuvectra is a company dedicated to

Join for free to read a longer excerpt or purchase this article

Interview with the CEO: Nuvectra Corporation (NASDAQ:NVTR)

Top Company Interviews

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS

Interview with the CEO: Nuvectra Corporation (NASDAQ:NVTR)

Top Company Interviews

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS